PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
September 07, 2023 10:00 ET
|
PainReform Ltd
TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
September 05, 2023 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the Second Quarter of 2023
August 10, 2023 16:05 ET
|
PainReform Ltd
TEL AVIV, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
July 19, 2023 09:00 ET
|
PainReform Ltd
TEL AVIV, Israel, July 19, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
July 14, 2023 14:35 ET
|
PainReform Ltd
TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
July 12, 2023 09:05 ET
|
PainReform Ltd
TEL AVIV, Israel, July 12, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
June 15, 2023 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
June 07, 2023 16:30 ET
|
PainReform Ltd
TEL AVIV, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
May 18, 2023 09:00 ET
|
PainReform Ltd
TEL AVIV, Israel, May 18, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the First Quarter of 2023
May 15, 2023 16:45 ET
|
PainReform Ltd
TEL AVIV, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...